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Summary BCNU (carmustine), VM26 (teniposide) and ARA-A5'P (vidarabin-monophosphate) were
compared in their activity against 30 cell lines of primary (N=21) and metastatic (N=9) human brain
tumours, which were characterized in tissue culture by cytochemical, immunological and cytogenetic criteria.
In vivo achievable concentration-time products c x t were correlated with in vitro pharmacokinetic data in
order to evaluate in vitro drug sensitivity at relevant exposure doses. A microcytotoxicity assay was employed
to screen for drug toxicity in individual tumour cell lines. Following drug exposure and 5 to 8 population
doubling times of untreated controls, RNA-synthesis - as a parameter of cell metabolism and proliferation -
was determined by incorporation of [5,6-3H]-uridine into cellular RNA (liquid scintillation counting protocol).
The cytotoxic effect of each drug on individual cell lines was expressed in terms of a sensitivity index (SI); by
these means effects of different drugs on individual tumour cell lines could be compared. Mean sensitivity
indices of ARA-A5'P, BCNU and VM26 for primary brain tumour cell lines were 0.59, 0.82 and 0.54. ARA-
A5'P and VM26 had almost similar activities against brain tumour cell lines, whereas BCNU was significantly
(P<0.001) less active. High grade gliomas were less sensitive to all three agents than low grade and
infratentorial gliomas. ARA-A5'P was also able to effectively reduce colony formation in brain tumour cell
lines. A cross-resistance of ARA-A5'P to either BCNU or VM26 could not be observed. Clearly, ARA-A5'P
is an effective drug in treatment of brain tumour cells in vitro.
Prognosis for patients with anaplastic gliomas (glioblastoma anti-herpes-virus drug in herpes-simplex encephalitis (Muller
multiforme, astrocytoma IV) is poor: median survival times et al., 1977; Whitley et al., 1977). ARA-A5'P (MW=335)
for surgery, radiotherapy and BCNU are 34.5 to 51 weeks penetrates the BBB very well, resulting in CSF levels of 60%
(Walker et al., 1978; Walker et al., 1980); only a small of the concurrent plasma levels (LePage et al., 1975;
proportion of patients will survive longer than 18 months. In Preiksaitis et al., 1981; Whitley et al., 1980). Its main modes
vitro assay systems have been developed to detect of action are competitive inhibition of cellular and viral
chemotherapy responders, to define alternative drug DNA replication systems, inhibition of the cellular DNA
regimens for non-responding patients, to avoid subjecting repair system, inhibition of ribonucleotide reductase,
patients to the toxicity of unnecessary chemotherapy, and inhibition of DNA- and RNA-directed DNA-synthesis,
finally to screen for new potentially acti've agents. Some in inhibition of adenylate-polymerase and finally incorporation
vitro systems showed a reasonable correlation with clinical into cellular and viral DNA and RNA (Muiller et al., 1977).
courses of patients, whose brain tumours had been tested Preliminary evidence of an anti-glioma activity of ARA-A5'P
(Bogdahn, 1983; Rosenblum et al., 1983; Thomas et al., has been deduced from previous in vitro work with ARA-A,
1979). However, the poor permeability of most drugs indicating efficacy in a number of brain tumours (Bogdahn,
through the blood brain barrier (BBB), and resulting brain 1983); the purpose of the preceding paper was mainly to
tumour exposure doses were not calculated. Therefore it was delineate a potential activity of ARA-A5'P in human brain
extremely difficult to estimate adequate in vitro tumour cells and to compare it with that of VM26 and
concentrations for the various screening procedures. In this BCNU, in order to estimate its potential relevance for
paper we have tried to reduce these limitations by strictly clinical therapy.
correlating in vivo and in vitro pharmacokinetic data
(exposure doses) of BCNU, VM26 and ARA-A5'P,
whenever possible applying CNS drug data. Materials and methods
We choose BCNU (carmustine; MW =218), mainly an
alkylating and carbamoylating, as well as DNA-crosslinking, Cell cultures
non cell cycle-phase specific agent (Tofilon et al., 1983) as a Cell cultures were established from biopsies of 30 patients
reference drug in our study, as most clinical studies on with primary and metastatic malignant brain tumours.
chemotherapy of malignant gliomas have been compared to Clinical data and final histological diagnoses, as well as
the activity of BCNU. The cell cycle phase specific epipodo- information on the clinical course of these patients are
phyllotoxin-derivative VM26 (teniposide; MW=656.5) is detailed in Table I. Biopsy material was disaggregated after
used in primary and secondary ,malignant brain tumours; removal of cell debris and macroscopic normal brain tissue.
penetration of the BBB is poor (Allen et at., 1975), but drug After preparation of a cell suspension in complete tissue
concentrations in brain tumour tissue have been determined culture medium (MEM, 20% FCS, 6 ugml-1 gentamycin,
(Stewart et at., 1984). Clinical results with this drug have 1 mmolP1 L-glutamine, non-essential amino-acids and
been controversial (Jamamoto et at., 1979; Kettinger et at., MEM-vitamins - Boehringer-Mannheim) cultures were
1979), therefore we were interested in its in vitro activity on propagated under standard tissue culture conditions (5%
human brain tumour cells. The purine analogue ARA-A5'P C02, saturated H20-atmosphere, 37°C). Subconfluent
was originally used as an anti-viral agent, especially as an cultures (NUNC-tissue culture flasks) were split 1:2 by
trypsinization (0.05-0.02% trypsin-EDTA in PBS -
Correspondence: U. Bogdahn. Seromed-Biochrome-KG). Subsequent early passage cells
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Table I Synopsis of clinical data and sensitivity indices for human brain tumour cell lines
No. Age Sex Histology Location X-Ray Chemotherapy Follow-up SIBCNU SIVM26 SIARHIA5P
3 72 M oligodendrogl. ri fr - 19 (R) 0.439 0.049 0.437
4 60 F oligodendrogl. ri par - 19 0.773 0.027 0.550
5 5 M mal.glioma IV IV ventr + PRC,VCR,MTX 11 (S) 0.031 0.026 0.024
6 63 M glioblastoma le par-occ + BCNU,VM26 12 (S) 0.056 0.124 0.105
7 23 M ependymoma L4/L5 + CCNU 17 (R) 0.063 0.096 0.045
10 16 F fibr.astrocyt. ri fr - 0.612 0.696 1.104
13 13 F osteoclastoma Th 3/4/5 - 1.116 0.616 1.083
19 29 M mal.melanoma ri temp - 12 (R) 0.776 0.8 0.524
25 58 F bronch.carc. L4/L5 + 0.842 0.46 0.769
26 62 F glioblastoma bi fr + BCNU,VM26 8 (S) 0.884 0.534 0.613
27 62 M glioblastoma le par-occ + BCNU;VM26 4 (S) 1.116 0.592 0.580
29 43 M mal.melanoma le par + 2 (R) 0.742 1.035 1.073
31 52 F meningeoma le fr-temp - 0.888 0.757 0.865
32 32 M astrocytoma II le temp-par + 9 0.993 0.616 0.521
35 63 M glioblastoma le par-occ + BCNU,VM26 6 (S) 0.900 1.08 0.827
36 65 F glioblastoma ri temp - 1 (S) 0.964 0.676 0.639
37 10 M hemangiopericyt. le par + 1.483 0.653 0.668
38 46 F oligo/astro II ri temp-par - 0.954 0.73 1.009
43 24 F Ewing sarcoma ri paravert. + ADR,CLC,VCR 13 (S) 0.852 0.364 0.449
46 59 M bronch.carc. le par + 1.270 1.0 0.644
47 16 F gangliolioma le par - - 1.071 0.311 0.250
48 23 M fibr.astrocyt. ri fr-temp + 1.436 0.319 0.179
49 48 M hypernephr.carc. ri occ + VBL 1.270 0.547 0.287
51 47 M bronch.carc. csf + MTX 1 (S) 1.071 0.443 1.070
53 53 F glioblastoma ri par-occ + BCNU 12 (S) 1.436 0.925 0.717
54 61 F thyroid carc. ri fr-temp - 1.873 0.813 0.689
55 33 M mal.glioma IV fr-bas + BCNU,VM26 10 (R) 1.215 0.971 1.116
56 62 F astrocytoma IV le fr + BCNU,VM26 10 (S) 0.771 0.567 0.479
57 26 M glioblastoma le fr-par + BCNU,VM26 8 (R) 0.987 0.692 1.031
60 19 F astrocytoma II le fr-temp + - 0.845 0.802 0.712
PRC=procarbazine; VCR =vincristine; MTX =methotrexate;
S=survival (time intervals in months).
experimentation. Tumour cells were characterized by cyto-
chemical analysis (HE-stain, PTAH-stain, Trichrome,
unspecified esterase, acid phosphatase, NADPH-stain),
detection of specific glial and tumour antigens (Thy-I -
Seeger et al., 1982; Ge 2 - de Tribolet et al., 1984; GFAP -
Eng et al., 1971; S-100, fibronectin, neurone-specific enolase,
transferrin-receptor, melanoma-associated antigen, keratin -
Dakopatts; HLA-A,B,C, HLA-DR- Becton-Dickinson) and
by cytogenetic analysis (karyotyping) (Bogdahn et al., 1985;
Bogdahn et al., in preparation). Glial tumours expressed at
least 3 of the typical antigens GFAP, Ge-2, S-100, Thy-I or
melanoma-associated antigens, usually in a non-
homogeneous pattern. Karyotypes were always pathological,
most cultures displayed near diploid karyotypes. Neuro-
pathological diagnosis of biopsies from which cultures were
derived are given in Table I.
Assay systems
Experiments to assess drug activity in different cell cultures
were performed with a microassay (Bogdahn, 1983; Bogdahn
et al., 1985): Single cells were plated into 96-well micro-tissue
culture plates (flat bottom - Costar) in complete tissue
culture medium. After 24h cells were treated with different
drugs either for 1 h or continuously, dependening on the cell-
cycle phase specificity of individual drugs (see below). They
were then allowed to proliferate under tissue culture
conditions for 5 to 8 population doubling times of untreated
controls, equalling 7 to 14 days (there was no correlation of
population doubling times to chemosensitivity); finally [5,6-
3H]-uridine (specific activity 27Cimmol-1, Amersham-
Buchler) incorporation was determined during a 6h
incubation period by a liquid scintillation counting protocol.
Each drug was tested at 4 concentrations; test points were
determined by 4 replicates, controls by 12 replicates. For
liquid scintillation counting cells were harvested by a cell
harvester (Skatron); radioisotope incorporation was
ADR =adriamycin; CLC=cyclophosphamide; R=recurrence;
measured by a Packard scintillation counter using Instagel
(Packard) and expressed as counts per minute (cpm); a range
of 2-20 x 103cpm was achieved in controls, standard errors
ranging from 2 to 10%. Inhibition of [5,6-3H]uridine-in-
corporation into cellular RNA (as a parameter of tumour
cell RNA-synthesis) was expressed as % RNA-synthesis of
treated cells relative to untreated controls. From these data
dose response curves for each drug and individual tumour
cell lines were derived.
In addition, for 3 cell cultures a human tumour cloning
assay was applied: In these experiments single cell
suspensions were plated into 6-well tissue culture dishes
(Costar) at different cell concentrations (tissue culture
medium containing 20% autologous conditioned medium).
Identical treatment protocols were performed as in the
micro-assay (cells were treated 24h after plating - treatment
prior to plating did not yield different results). Controls were
performed as 6 replicates, test points determined as 3
replicates. After 3 to 4 weeks the culture dishes were stained
with concentrated Giemsa solution and the number of
tumour cell colonies counted with an inverted microscope
(Wild), a colony being defined as 50 or more tumour cells
derived from a single plated cell. The number of colonies per
number of plated tumour cells was defined as colony
forming efficiency (CFE). The drug effect was calculated as
the ratio of colony forming efficiencies of treated cultures
relative to untreated control cultures. This ratio was defined
as surviving fraction (SF) in drug treated cultures.
Pharmacology
For each of the drugs employed in the experiments in vitro
and in vivo pharmacological data had to be obtained:
BCNUJ Data on in vivo pharmacokinetics of BCNU have
been 'adopted from Levin et al. (1975). Corresponding in
vitro data on terminal half life and peak concentrations in
the in vitro system have been determined by Giannini & LevinVM26 ACTIVITY AGAINST BRAIN TUMOURS IN VITRO 155
(unpublished data). A 1 h exposure time was chosen for in
vitro experiments, as BCNU acts mainly as a cell cycle phase
non-specific agent and as it is clinically applied as a bolus
infusion (30min); there were actually no significant
differences in chemosensitivities between 1 h and continuous
BCNU exposures.
VM26 In vivo pharmacological data were obtained from
the literature (Allen et al., 1975; Stewart et al., 1984). Brain
tumour pharmacokinetics were considered more reliable. In
vitro pharmacokinetic parameters were derived from our own
experiments employing an in vitro bioassay: Cell cultures
were exposed to VM26 for different time periods and
supernatants of these experiments were collected and stored
immediately in liquid nitrogen. In a second experiment
identical cell cultures were exposed to these supernatants,
containing active drug in decreasing concentrations related
to in vitro drug decay. The results expressed as inhibition of
RNA synthesis could be transformed to VM26 con-
centrations, as these experiments were performed in an
almost linear part of the dose response curve for VM26: an
analysis of regression revealed a 1st order decay reaction
( = -0.984). From these data in vitro pharmacokinetic
parameters for VM26 were calculated. For in vitro
experiments, a continuous exposure was chosen, as VM26
acts as a cell cycle phase specific (G2-M-phase) agent.
ARA-A5'P In vivo pharmacokinetic data were taken from
the literature (LePage et al., 1975; Preiksaitis et al., 1981).
For determination of in vitro pharmacokinetic data cell
cultures were exposed to ARA-A5'P at different time
intervals; supernatants were stored in liquid nitrogen and
later assayed for ARA-A5'P-concentrations employing an
HPLC-protocol. For in vitro experiments a continuous
exposure was chosen, as the drug acts as a cell cycle S-phase
specific agent.
Correlation ofin vitro andin vivopharmacokinetics For the 3
drugs a linear correlation curve of c x t .(concentration time
product=,umol x h 1- 1)-values and in vitro drug
concentrations (pmol -1) was established, employing in vitro
pharmacokinetic data. In vivo achievable maximal
concentration time products for respective drugs were then
correlated to a corresponding in vitro drug concentration,
resulting in a maximal in vitro exposure dose equivalent to
the maximal in vivo exposure dose: this in vitro concentration
was called the 'cut-off'-concentration (Alberts et al., 1980;
Ali-Osman et al., 1983 - see below).
Evaluation ofin vitro results Dose response curves for each
drug were evaluated in a concentration range from the
lowest concentration to the in vitro 'cutoff-concentration:
The drug effect on each individual tumour cell line was
expressed in terms of a sensitivity index SI, as defined by:
SI=AUC./AUC,., (Ali-Osman et al., 1983); AUCX is the
area under the dose response curve of the individual tumour
cell line from lowest drug concentration to the 'cut-off'-
concentration and AUCCut is the area under the theoretical
dose response curve with the identical concentration range
and theoretical 100% tumour cell survival.
Statistical analysis ofsensitivity indices Sensitivity indices of
each cell line for the 3 different drugs were compared
statistically; the Students' t-test for unrelated pairs was
applied.
Results
Pharmacology
BCNU An in vitro 'cut-off'-concentration of 9.0pmoll-1
was found (see Table II) for a 1 h exposure.
VM26 The in vivo pharmacokinetics revealed an almost
linear time dependent decay of VM26 (correlation coefficient
r= -0.984) (Figure 1). By performing a linear regression
analysis, a terminal half life of 43.2h was calculated
(Table II); an in vitro 'cut-off'-concentration of 0.15 imolI1
was found for continuous exposure (tissue). If in vivo plasma
pharmacokinetic data would have been taken for correlation,
a 'cut-off' concentration of 3.5 umol P1 would have been
found (plasma).
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Figure 1 In vitro pharmacokinetics of VM26, determined with
an in vitro bioassay, with an initial concentration of
3.15umoll 1
ARA-A5'P In vitro pharmacokinetics followed a first order
reaction: a terminal in vitro half life of 2.6h could be
calculated (Table II; Figure 2), which resulted in an in vitro
'cut-off' concentration of 75 imol1- 1 for continuous
exposure. As serum deaminase activity in individual patients
(and therefore drug inactivation) may vary widely, we
selected a 20% value of the calculated 'cut-off' concentration
of only 15imoll-1 to exclude an artificially high exposure
dose.
Table II Synopsis of pharmacokinetic data for BCNU, VM26 and ARA-A5'P
peak Cc T112(h) c xtd 6cut-OfC Reference
BCNU: in vivo: 9.2 1.13 4.77 - Levin, 1975
in vitro: 0.35 9.0 (1 h) Giannini & Levin
(unpublished)
VM26: in vivo:a 21.5 8.88 107.7 Allen & Creaven, 1975
in vivo:b 0.39 5.25 Stewart et al., 1984
in vitro: 43.2 0.15 (ctd)
ARA-A5'P: in vivo: 30.0 0.14-4.5 287.1 LePage et al., 1975
Preiksaitis et al., 1981
in vitro: 2.6 75 (ctd)
aplasma; btumour tissue,(1 h/ctd): exposure 1 h or continuous; CIjmol -1;diimol.hl-1.
r
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Figure 2 Pharmacokinetics of ARA-A5'P in vitro, determined
by HPLC-protocol. For details see text.
Drug effects
Typical dose response curves obtained with BCNU, VM26
or ARA-A5'P are illustrated in Figures 3a-c. Sensitivity
indices were calculated for each tumour cell line for the 3
drugs, as shown in Table I. Mean sensitivity indices of
primary malignant and metastatic brain tumours may be
seen in Table III, clearly metastatic brain tumours are less
sensitive to all 3 agents than primary CNS neoplasms. Cell
cultures with SI-values lower than 0.8, 0.5 and 0.2 are also
depicted in Table IV. Sensitivity indices of each cell line for
the 3 different drugs are depicted in Figure 4. If sensitivity
indices of the 3 different drugs were compared on a
statistical basis for each individual cell line, ARA-A5'P and
VM26 were significantly more effective against brain tumour
cell lines than BCNU (P<0.001). Differences between ARA-
A5'P and VM26 were not significant. Cell cultures were also
analysed for histology-related chemosensitivity (Table V):
High grade malignant brain tumours generally were more
resistant to the 3 drugs than low grade and infratentorial
tumours.
Drug effects of ARA-A5'P on tumour colony progenitor
cells were comparable to the effects seen in the micro-assay:
results for 3 different cell lines may be seen in Table VI;
colony formation was significantly inhibited by ARA-A5'P
at a concentration of 15,imol 1-1.
Table III Synopsis of mean sensitivity indices for human brain
tumour cell lines
SIBCNU SIVM26 SIARA-AS5P
Primary CNS tumours 0.819 0.535 0.594 (n=21)
Metastatic tumours 1.052 0.675 0.732 (n=9)
Table IV Efficiency of active compounds in human brain tumour
cell lines
BCNU VM26 ARA-A5'P
CNS tumours SI<0.8 7 18 15
SI <0.5 4 7 7
SI <0.2 3 5 4
Metastatic tumours SI<0.8 2 6 6
SI <0.5 3 3
SI <0.2 -
j \ \0 48
0~~~~~~~~~1
19
0
cut-off: 9.0,umol 1-
6
l8 5
0.2 0.9
h
0.060.3
c
1.5
1.0 _
0.5 _
0 _
4.7
BCNU-concentration ,umol 1-'
23.4
1.5 7.8
VM-26 concentration ,umol l-1
00.6 3 15
ARA-A5'P concentration ,umol 1`
Figure 3 Typical dose-response curves representing the effects
of BCNU (a), VM26 (b) and ARA-A5'P (c) on RNA-synthesis
of tumour cells.
Table V Correlation of sensitivity index with tumour histology
Astrocytomas GR.IV Low-GR. gliomas (n=9)
glioblastomas (n = 10) infratentor. tumours
BCNU SI =0.836 a=0.434 SI =0.765 a =0.382
VM26 SI =0.619 a =0.323 SI =0.421 a=0.282
ARA-A5'P SI =0.68 a =0.284 SI =0.569 a =0.345
Table VI Comparison of ARA-A5'P activity in a
colony forming assay and in the microassay
Cell line 43 48 49
Surviving fraction (CFE) 0.64 0.11 0.08
Surviving fraction (RNA) 0.41 0.16 0.17
CFE =colony forming assay; RNA =micro-
proliferation assay; SF(RNA) represents RNA synthesis
in remaining tumour cells relative to that of controls.
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Figure 4 Synopsis of sensitivity indices for ARA-A5'P, BCNU
and VM26, with mean values (incl. s.d.) for primary CNS
tumours, metastatic CNS-tumours and all cell lines.
Discussion
This study was intended to compare the anti-brain tumour
activities of BCNU, with VM26, which is currently under
clinical investigation for treatment of this class of tumour,
and ARA-A5'P, which has not yet been used for treatment
of CNS neoplasms. An in vitro comparative study was
performed with a microsystem that had earlier shown a good
correlation between in vitro chemosensitivities of human
malignant brain tumour cells towards BCNU and the clinical
course of patients being treated with nitrosoureas (Bogdahn,
1983). In this present study 3 out of 21 primary brain
tumour cell lines (14.3%) displayed high sensitivity to
BCNU (SI<0.2). This proportion correponds to the number
of longterm survivors among patients with anaplastic
gliomas treated with BCNU (Liebermann et al., 1982;
Walker et al., 1978, 1980). As clinical results for BCNU
chemotherapy in brain tumour patients were reproduced
fairly consistently in several clinical trials, and in vitro results
were in good concordance with clinical experience, BCNU
was chosen as a drug of reference in this in vitro
investigation.
The results of previous clinical studies (Jamamoto et al.,
1979; Kettinger et al., 1979) on the activity of VM26 on
human malignant brain tumours are controversial; our
results indicate high in vitro activity of this compound,
superior to that of BCNU. Pharmacokinetic parameters for
our experiments have respected the dose modifying effects of
the BBB on VM26-brain tumour tissue concentrations under
experimental conditions (Stewart et al., 1984); the clinical
mode of application (30min infusion) should be reconsidered
critically - perhaps a continuous infusion might reflect the
drugs cell cycle phase specific activity in an optimal fashion.
Preliminary observations indicate anti-tumour activity of
ARA-A5'P in in vitro systems (Bogdahn, 1983; Kufe et al.,
1983) and in some animal tumour systems (Bodey et al.,
1975, 1977). From previous studies on pharmacology
(LePage et al., 1975; Preiksaitis et al., 1981) and on
treatment of herpes simplex encephalitis (Whitley et al.,
1977), the drug was known to have a high permeability
through the BBB ('60% of concurrent plasma levels may
be found in the CSF). For these reasons ARA-A5'P seemed
to be an attractive drug for further studies on activity
against brain tumour cells. As variations in individual
patients serum deaminase activity result in variable drug
inactivation, we have employed only one fifth of the
maximum achievable in vivo concentration time product for
in vitro experiments; so drug activity demonstrated in our
experiments will even reflect that activity that may be
anticipated in those patients with extremely high serum
deaminase activity and rapid drug inactivation. In this study
we could clearly demonstrate that ARA-A5'P has high
activity against human malignant glial tumour cells in vitro,
since it was significantly more active (P<0.001) than BCNU
(see Tables I, III, IV, Figure 5). It was less active in
metastatic brain tumours than in primary brain tumour cells,
which was also the case for the other 2 drugs we tested. In
these experiments we did not find an indication for cross-
resistance of ARA-A5'P to either VM26 or BCNU. In
addition, ARA-A5'P was able to inhibit growth of brain
tumour colony progenitor cells in a comparable fashion to
the results obtained with the microassay (Table VI).
Compared to BCNU, which has rather significant
pulmonary, renal, and bone marrow toxicity (MacDonald et
al., 1981; West et al., 1983), ARA-A5'P appears to be less
toxic. Its toxic side effects (bone marrow depression,
hepatotoxicity, CNS toxicity - tremor and myoclonus) were
all reversible within 2 weeks at most and observed mainly
under extremely high dosage (Preiksaitis et al., 1981; Whitley
et al., 1980; Kurtz, 1975). Insufficient renal function may
require dose reduction of the compound.
In conclusion, we could demonstrate high activity of
ARA-A5'P in human brain tumour cell lines in vitro. This
compound has excellent pharmacokinetic characteristics for
prospective application as a chemotherapeutic agent in brain
tumour therapy, it is relatively well tolerated and rather non-
toxic compared to BCNU; its activity is significantly
superior to BCNU in our experiments and comparable to
the activity of VM26. As a result of this study we propose
that ARA-A5'P should be considered for future clinical
investigation in brain tumour therapy. In vitro results with
VM26 indicate higher in vitro activity than found clinically
so far - a proposal is made for a modified clinical drug
application as a continuous application rather than a bolus
infusion. We could also demonstrate that there is a
proportion of metastatic brain tumours which is
chemosensitive to agents active against primary CNS
neoplasms; individual chemosensitivity screening might be
helpful to identify these potential chemotherapy responders.
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